Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by Alba1314on Jul 31, 2018 7:47am
145 Views
Post# 28389714

RE:RE:RE:Position

RE:RE:RE:PositionI agree with most of what regardless is saying with one exception: I dont beleive a pp would be done at $0.10. There is zero incentive for a private placement at market value. If a pp is done at sp, there will be some sort of offering of cheaper shares at a future value, diluting the share base. That, or a straight pp done for less than current the sp, which again, dilute current share value. Either way, I think the sop will drop with a private placement. 

A joint venture, on the other hand, would send the sp upwards due to shared risk and no dilution.

However you look at it, this stock is still worth the risk. It's a 50/50 chance of making money. The trials are going to be positive or negative. if you think positive buy and hold. If not, short the stock near the end of the trial. 

Any other BS about the daily sp going up or down is for day traders.
<< Previous
Bullboard Posts
Next >>